- Viatris Inc. previously announced that the U.S. FDA accepted for review its New Drug Application for MR-107A-02, a fast-acting oral meloxicam for moderate-to-severe acute pain, with a PDUFA goal date of December 27, 2026.
- This investigational non-opioid, supported by two positive Phase 3 post-surgical pain trials, highlights Viatris’ push into higher-value, innovative pain therapies.
- Now we’ll examine how progress on this non-opioid, fast-acting meloxicam candidate could influence Viatris’ investment narrative and future earnings mix.
AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Viatris Investment Narrative Recap
To own Viatris, you need to believe that management can gradually shift the business mix away from lower-margin generics and toward higher-value, branded and complex medicines while controlling leverage. The FDA review of fast-acting meloxicam fits that story, but with a PDUFA date in late 2026, it does not materially change the near term earnings picture or the key risks around pricing pressure, regulatory scrutiny, and ongoing reliance on mature, off-patent products.
The most relevant recent announcement here is the reaffirmation of 2026 revenue guidance at US$14.45 billion to US$14.95 billion in early May. That guidance sets a reference point for how much impact, if any, fast-acting meloxicam and other value-added medicines will eventually need to have to meaningfully change Viatris’ earnings mix, especially if generic price erosion and regulatory costs continue to weigh on margins.
Yet behind the potential of non opioid acute pain drugs, investors should also be aware of...
Read the full narrative on Viatris (it's free!)
Viatris' narrative projects $15.4 billion revenue and $954.5 million earnings by 2029. This requires 1.8% yearly revenue growth and a $1.251 billion earnings increase from -$296.5 million today.
Uncover how Viatris' forecasts yield a $17.50 fair value, a 8% upside to its current price.
Exploring Other Perspectives
While the consensus sees meloxicam as part of a slow shift toward higher value products, the most pessimistic analysts were assuming roughly flat revenues near US$14.3 billion and only about US$94 million of earnings by 2028, so this new pain asset could prove more important to the story than those earlier forecasts suggest.
Explore 7 other fair value estimates on Viatris - why the stock might be worth over 2x more than the current price!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Viatris research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Viatris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viatris' overall financial health at a glance.
Ready For A Different Approach?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 12 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com